Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324
about
Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancerMolecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinomaNovel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapiesNovel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancerCombining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC50 Years of progress in the systemic therapy of non-small cell lung cancerMonoclonal antibodies for the treatment of cancerCetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision.Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinomaProgress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancerA phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagusEGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324.Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair.Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumorsFollowing the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapyFeasibility of cetuximab and chemoradiotherapy combination in Chinese patients with unresectable stage III non-small cell lung cancer: a preliminary reportStandard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factoAdding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung CancerPersonalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer.Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancerPooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent ChemoradiotherapyChemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancerCombined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations.Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells.Opportunities and challenges in the era of molecularly targeted agents and radiation therapyA Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer.EGFR inhibition in non-small cell lung cancer: current evidence and future directionsTherapeutic management options for stage III non-small cell lung cancer.ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancerA review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancerReversion of the ErbB malignant phenotype and the DNA damage response.Monoclonal antibodies in lung cancer.Recent advances in radiotherapy for thoracic tumours.
P2860
Q24187972-7CB2DBAB-1B3C-44FB-9D62-83CFF8FE3F25Q26767182-8C6A3236-A976-47C6-908E-AB651B7CAF4AQ26775388-453AD9C4-AD4F-487D-8139-A78DAE45DE53Q26827571-B3890EB6-317A-44E3-BF62-2157C9228383Q26852202-88ACD930-780C-423D-AB71-DCBA344C2D2DQ27014978-E6A359E5-47CF-4164-BBFF-EA75E5DCCAA6Q27025966-663D204B-5AF3-4AA2-A786-91F1954AE153Q27329648-4BEEC62C-438B-47B2-B777-7DDFDA1C865DQ33583931-12F95736-BB72-4857-B5A9-69019399D9A2Q33711287-2AB470D7-1E8A-4CAB-972C-B3370B49F5E1Q33720025-D34BAA07-2115-436A-99E9-3C5AEE0E538CQ34041735-AD859D3A-D2A2-43AF-9C12-3DC2BED716A8Q34061012-B48FF19F-86A8-4612-B573-8FE4D1EBE85CQ34216725-C54F56A4-EC5D-4D51-82D7-4FB1E4EE5815Q34462689-FFBFF3DE-3544-4FDD-B298-664B8DD697FDQ34782417-705FF424-C7EF-4A08-A01F-6D30051706EFQ34970294-46CC23C6-85F6-4624-A06E-7F65AA08F21CQ35051964-CE3D3A18-FCA4-4942-83CC-F08EC9CB97ACQ35200424-066E647A-2511-498E-80FC-6B2DA6FFCC4EQ35538759-B7E72355-87BF-48AD-BB6D-01BF9BD392E0Q35568485-793F55D9-7FB5-427F-B4DD-8C7FF2311B69Q35608002-D0197A23-CE04-4778-BF95-71269E1B70F3Q36089579-E39919C7-2AD3-4E53-B060-572A3FD1BEF4Q36143838-E1790454-3FC4-4CCE-99A8-AE3946DDC92BQ36368864-7F0321F2-38ED-4227-B85D-672A8E7AD2B1Q36482508-58EBBD77-7055-49B2-88A8-5FEE06933018Q36989648-46B5639F-93DC-4046-932D-7CC0B96663F2Q36993644-1A70DAB8-B5D3-4502-AC22-F01EEFDF8D04Q36999705-4D312C81-1551-4649-B705-A10EF5C9C21DQ37028027-0D5160C1-C554-4B1E-BEEC-18409D1D4DBEQ37069689-C8EDF619-1826-4062-B9DF-5B94F1EB4BADQ37126741-6B8EC0C4-7582-4203-9A05-683084BF7185Q37180302-D9FAB235-16F0-409E-B91E-26F86CB0CE68Q37642455-3758BEE2-BB58-4203-A277-501E2F87558BQ37661108-E4228587-FCBD-4DFF-AD85-55529C267EEBQ37716645-BBAE2F31-038E-4225-8C6A-713263BCC273Q37975010-560EE52D-6728-4BB8-9BFE-96FF22164FE3Q38047648-BC451B8B-97C6-4579-8EAC-89187B08A1F9Q38067454-54261593-E6DF-4FFD-84C1-7568341936A1Q38155854-84503369-CB0E-4F0F-BA5D-5BED04593464
P2860
Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase II study of cetuximab in ...... ll-cell lung cancer: RTOG 0324
@ast
Phase II study of cetuximab in ...... ll-cell lung cancer: RTOG 0324
@en
type
label
Phase II study of cetuximab in ...... ll-cell lung cancer: RTOG 0324
@ast
Phase II study of cetuximab in ...... ll-cell lung cancer: RTOG 0324
@en
prefLabel
Phase II study of cetuximab in ...... ll-cell lung cancer: RTOG 0324
@ast
Phase II study of cetuximab in ...... ll-cell lung cancer: RTOG 0324
@en
P2093
P2860
P50
P356
P1476
Phase II study of cetuximab in ...... ll-cell lung cancer: RTOG 0324
@en
P2093
Francisco Robert
Philip O Doescher
Rebecca Paulus
Walter J Curran
P2860
P304
P356
10.1200/JCO.2010.31.7875
P407
P577
2011-05-09T00:00:00Z